Clinical Trial Update: ReVeRA-201: Etripamil in Atrial Fibrillation, Phase 2 [Phase 2]

View source ↗

Summary

Milestone Pharmaceuticals reports Phase 2 ReVeRA-201 results for etripamil in atrial fibrillation; the study has completed and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Etripamil (etripamil)

Snippet

Sponsor: Milestone Pharmaceuticals Inc. | Conditions: Atrial Fibrillation | Phase 2 | Status: COMPLETED | Results posted: 2024-09-19